Drug
Valganciclovir CMV Prophylaxis
Valganciclovir CMV Prophylaxis is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Recruiting1
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (66.7%)
Phase 41 (33.3%)
Trials by Status
recruiting133%
completed133%
not_yet_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_4
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
NCT07571135
recruitingphase_3
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
NCT06798909
completedphase_3
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
NCT00372229
Clinical Trials (3)
Showing 3 of 3 trials
NCT07571135Phase 4
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
NCT06798909Phase 3
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
NCT00372229Phase 3
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3